Skip to main content
Menu

Posts tagged with "Drug Development"

  • Chemical News

    The Cyclofluidic Story

    The recent post here on automation in chemistry (especially medicinal chemistry) is a good intro for this paper in ACS Med. Chem. Letters. It’s from David Parry, who led Cyclofluidic, and I’ve blogged about them a few times over the years. That was a company formed in 2008 in the UK to try to develop… Read More
  • Academia (vs. Industry)

    Where Drugs Come From: A Comprehensive Look

    This is a solid article by Jeffrey Flier (open-access in the Journal of Clinical Investigation) on the roles of academia and industry in drug discovery. Which is a topic that refuses to go away. I am prepared to swear that before starting this blog I had no idea of how many people are convinced that… Read More
  • Drug Development

    The Latest on Drug Failure and Approval Rates

    We now have an updated look at clinical success rates in the industry, and it’s a timely topic. Last year there were 59 approvals by the FDA (a new record), and the year before was good as well. So the question is always whether such numbers are artifacts, random noise, or part of a real… Read More
  • Academia (vs. Industry)

    From Industry to Academia

    Academic research and industrial drug discovery have always been on separate paths, but my impression is that the two understand each other better now than they have at any time during my career. That’s in no small part due to the number of industrial scientists who have moved into academia (itself in no small part… Read More
  • Animal Testing

    Enough With the Mouse Behavioral Models?

    This piece in STAT is well worth a read. The author, Adam Rosenberg of Rodin Therapeutics, is ready to ditch rodent-centric models for human CNS disease, and I can see where he’s coming from. I’ve often said that when I think back on my Alzheimer’s and schizophrenia drug discovery days (back when I was first… Read More
  • Business and Markets

    Sorrento Therapeutics Is Not Happy

    I have not been a fan of Patrick Soon-Shiong and his approach to the biopharma business (and the publicity thereof). There’s a new lawsuit that (should its accusation hold up) will make anyone even less of a fan. Here’s a rundown at Endpoints, and one at Forbes. It’s a mess, so I’ll try to untangle… Read More
  • Cancer

    No Pain, and No Worries?

    The FAAH (fatty acid amide hydrolase) enzyme system has provided a number of headlines over the years. FAAH itself is involved in the brain’s endocannabinoid system – it clears neurotransmitters like anandamide – and a number of other biologically important hydroxyethylamide and acyltaurines. So the potential for inhibitors of it… Read More
  • Business and Markets

    Zafgen: Will There Be a Third Act?

    A few years ago on this blog, I wrote several times about a small company called Zafgen and their unusual epoxide-based chemical matter (beloranib) that was in development for the rare Prader-Willi syndrome. That’s a genetic disorder that includes, among many other problems, constant hunger (with the complications that you’d expect fro… Read More
  • Drug Assays

    Experiences With Phenotypic Screening?

    Very little blogging time today, but I wanted to throw a question out to the readership instead. I’m at the Keystone conference on Phenotypic Drug Discovery, so here’s a relevant topic: what are your own experiences with phenotypic screening? Background for those outside the field: broadly speaking, you can sneak up on a drug by… Read More
  • Business and Markets

    Institutional Memory

    This is a topic that came up in the comments section of a post last week, but it’s important enough that I wanted to give it some exposure here on the front page. It was a question from someone outside the industry, who asked about how companies can retain “institutional memory”, what with all the… Read More
123...